Setting Up and Running a Tougher Supplier Audit Program

Some of these sessions are too basic - this one had a good mix of basic and details. The tips are helpful. One comment: a little more discussion regarding the use of Detection in FMEAs would be useful since many do not advocate its use. Thanks,

I especially liked that the Q&A session after the webinar was long enough to not only address my own questions but also to learn from the questions from the other participants in the webinar.

Very thorough understanding of the history/progression of the guidances, and very helpful evaluation of current and potential directions. Excellent presentation skills, very engaging.

Subscribe Newsletter

Main
SOX Compliance
Setting Up and Running a Tougher Supplier Audit Program

Setting Up and Running a Tougher Supplier Audit Program

| |

Instructor : John E Lincoln

Product Id : 600102

Overview: The last few years have seen the U.S. FDA come under increasing negative public scrutiny.

High profile drug recalls, food chain problems and contamination, import problems, resignations. Now a new commissioner vows no more "business as usual". Data in submissions and decisions rendered will be more science based. Most Warning Letters will not have an initial judicial review, resulting in more and faster Warning Letter filings. Larger, higher profile companies are coming under FDA investigation activities. A key area gaining attention is a company’s suppliers, for both services and products / components. Why needed? FDA expectations? How are successful companies meeting this challenge. Tools that need to be put in place or enhanced. Getting supplier buy-in. Coping with "rogue" suppliers.

Areas Covered in the Session:

Regulatory "Hot Buttons"
Classify suppliers
Supplier requirements by "classification"
The site audit
Types of remote audits
Maintaining the relationship

Who Will Benefit:

Senior Management, Project Leaders, Internal / External Consultants
Mid-level management and supervisory personnel
Corporate and site coordinators
Regulatory Affairs
Quality systems personnel / QAE
R&D and engineering staff
Purchasing personnel
New product development personnel

John E. Lincoln is a medical device and regulatory affairs consultant. He has helped companies to implement or modify their GMP systems and procedures, product risk management, U.S. FDA responses. In addition, he has successfully designed, written and run all types of process, equipment and software qualifications/validations, which have passed FDA audit or submission scrutiny, and described in peer-reviewed technical articles, and workshops, world wide. John has also managed pilot production, regulatory affairs, product development/design control, 510(k) submissions, risk management per ISO 14971, and projects; with over 28 years of experience in the FDA-regulated medical products industry - working with start-ups to Fortune 100 companies, including Abbott Laboratories, Hospira, Tyco/Mallinckrodt. He is a graduate of UCLA.

Related Webinars:

No Related Webinars Available